Your browser doesn't support javascript.
loading
Pharmacological restoration and therapeutic targeting of the B-cell phenotype in classical Hodgkin lymphoma.
Du, Jing; Neuenschwander, Martin; Yu, Yong; Däbritz, J Henry M; Neuendorff, Nina-Rosa; Schleich, Kolja; Bittner, Aitomi; Milanovic, Maja; Beuster, Gregor; Radetzki, Silke; Specker, Edgar; Reimann, Maurice; Rosenbauer, Frank; Mathas, Stephan; Lohneis, Philipp; Hummel, Michael; Dörken, Bernd; von Kries, Jens Peter; Lee, Soyoung; Schmitt, Clemens A.
Afiliação
  • Du J; Medical Department of Hematology, Oncology, and Tumor Immunology, and Molekulares Krebsforschungszentrum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Neuenschwander M; Center of Cancer Research, Binzhou Medical University Hospital, Binzhou, People's Republic of China.
  • Yu Y; Screening Unit, Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany.
  • Däbritz JH; Max-Delbrück-Center for Molecular Medicine, Helmholtz Association, Berlin, Germany.
  • Neuendorff NR; Medical Department of Hematology, Oncology, and Tumor Immunology, and Molekulares Krebsforschungszentrum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Schleich K; Medical Department of Hematology, Oncology, and Tumor Immunology, and Molekulares Krebsforschungszentrum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Bittner A; Medical Department of Hematology, Oncology, and Tumor Immunology, and Molekulares Krebsforschungszentrum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Milanovic M; Medical Department of Hematology, Oncology, and Tumor Immunology, and Molekulares Krebsforschungszentrum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Beuster G; Medical Department of Hematology, Oncology, and Tumor Immunology, and Molekulares Krebsforschungszentrum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Radetzki S; Max-Delbrück-Center for Molecular Medicine, Helmholtz Association, Berlin, Germany.
  • Specker E; Screening Unit, Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany.
  • Reimann M; Screening Unit, Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany.
  • Rosenbauer F; Medical Department of Hematology, Oncology, and Tumor Immunology, and Molekulares Krebsforschungszentrum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Mathas S; Institute for Molecular Tumor Biology, Westfälische Wilhelms-Universität, Münster, Germany.
  • Lohneis P; Medical Department of Hematology, Oncology, and Tumor Immunology, and Molekulares Krebsforschungszentrum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Hummel M; Max-Delbrück-Center for Molecular Medicine, Helmholtz Association, Berlin, Germany.
  • Dörken B; Institute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany; and.
  • von Kries JP; Institute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany; and.
  • Lee S; Berlin Institute of Health, Berlin, Germany.
  • Schmitt CA; Medical Department of Hematology, Oncology, and Tumor Immunology, and Molekulares Krebsforschungszentrum, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Blood ; 129(1): 71-81, 2017 01 05.
Article em En | MEDLINE | ID: mdl-27733358
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Linfócitos B / Diferenciação Celular / Transcriptoma / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Linfócitos B / Diferenciação Celular / Transcriptoma / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha